touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder.
The abstract ‘A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder (NCT04658862)’ (abstract number TPS4586) was presented at the 2021 ASCO Annual Meeting.
DOI: 10.1200/JCO.2021.39.15_suppl.TPS4586 Journal of Clinical Oncology 39, no. 15_suppl
Questions
1. What risks are associated with radical cystectomy in the treatment of muscle-invasive bladder cancer? (00:35-01:43)
2. Could you tell us a little about the TAR-200 drug delivery system and the rationale for combining its use with systemic cetrelimab in muscle-invasive bladder cancer? (01:43-02:30)
3. What are the aims and design of the SunRISe-2 study? (02:30-03:24)
4. What are the eligibility criteria of the study? (03:24-04:44)
5. What are the study endpoints? (04:44-05:35)
6. When are data expected to be presented? (05:35-07:05)
Disclosures: Consultant for Photocure and UroToday; travel fees and advisory board for Janssen.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
